GlassScriptPhysician profile
Brandon C Mickelsen
NPI 1417987686
$1,800.35
in general payments reported to CMS, 2019-2025
29 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $281 · 2021: $301 · 2022: $398 · 2023: $147 · 2024: $166 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $401.48 | 2019-2025 | Repatha, Otezla |
| Abbvie INC. | $240.88 | 2021-2024 | |
| Astellas Pharma US INC | $209.30 | 2019-2025 | Veozah |
| Novo Nordisk INC | $134.14 | 2019-2025 | Ozempic, Rybelsus |
| Grifols USA, LLC | $130.89 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $92.05 | 2021-2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $42.76 | 2019-2020 | |
| Glaxosmithkline, LLC. | $41.75 | 2019-2024 | Arexvy, Bexsero, Shingrix |
| Allergan, INC. | $39.24 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $38.33 | 2020-2025 | Enflonsia, M-M-R II, Gardasil 9 |
| Lilly USA, LLC | $37.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $32.44 | 2022-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $32.12 | 2025 | |
| Nestle Healthcare Nutrition INC. | $29.13 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $29.12 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $26.39 | 2024 | Fluad, Flucelvax |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.14 | 2019 | |
| Sumitomo Pharma America, INC. | $23.81 | 2025 | Gemtesa |
| Genentech USA, INC. | $22.55 | 2021 | |
| Mylan Specialty L.P. | $21.53 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $20.98 | 2022 | |
| Abbott Laboratories | $19.93 | 2022 | |
| Dexcom, INC. | $18.88 | 2024 | Dexcom G6 Transmitter |
| Alnylam Pharmaceuticals INC. | $17.67 | 2023 | Amvuttra |
| Neurocrine Biosciences, INC. | $17.41 | 2025 | |
| Roche Diagnostics Corporation | $15.28 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.18 | 2025 | Fanapt |
| Mayne Pharma Commercial LLC | $12.44 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Mickelsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.